Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The ...

Kenneth Patrick Lorton, the Executive Vice President, Chief Technology Officer, and Chief Operating Officer of Software (ETR:SOWGn) at Schrodinger, Inc. (NASDAQ:SDGR), recently sold 985 shares of the ...

Schrödinger’s software platform is built on more than ... To learn more, visit www.schrodinger.com, follow us on LinkedIn, or visit our blog, Extrapolations.com ...

Despite trading around its all-time low just five years post-IPO, Schrödinger has consistently grown its software revenue, underpinning its valuation challenge as a hybrid of biotech and software.

The companies also announced an expanded three-year software agreement that substantially increases Novartis’s access to Schrodinger’s computational predictive modeling technology and ...

Schrödinger will report its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after the ...

Yousif Capital Management LLC cut its stake in Schrödinger, Inc. (NASDAQ:SDGR – Free Report) by 2.4% in the fourth quarter, ...

We advanced the capabilities of our computational platform and leveraged the synergies in our business, which included signing a multi-target research collaboration and expanded software licensing ...